UBS Group’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $313M | Buy |
4,463,211
+55,304
| +1% | +$2.86M | 0.04% | 454 |
|
|
2026
Q1 | $224M | Buy |
4,407,907
+321,141
| +8% | +$15M | 0.03% | 565 |
|
|
2025
Q4 | $121M | Sell |
4,086,766
-714,781
| -15% | -$19.4M | 0.02% | 890 |
|
|
2025
Q3 | $124M | Buy |
4,801,547
+859,315
| +22% | +$24M | 0.02% | 879 |
|
|
2025
Q2 | $109M | Sell |
3,942,232
-2,435,305
| -38% | -$64.1M | 0.02% | 908 |
|
|
2025
Q1 | $181M | Buy |
6,377,537
+1,304,166
| +26% | +$46.3M | 0.03% | 566 |
|
|
2024
Q4 | $211M | Buy |
5,073,371
+2,804,243
| +124% | +$134M | 0.04% | 485 |
|
|
2024
Q3 | $152M | Buy |
2,269,128
+1,187,367
| +110% | +$109M | 0.03% | 528 |
|
|
2024
Q2 | $128M | Buy |
1,081,761
+64,573
| +6% | +$8.17M | 0.03% | 522 |
|
|
2024
Q1 | $108M | Buy |
1,017,188
+143,919
| +16% | +$14.5M | 0.03% | 614 |
|
|
2023
Q4 | $86.8M | Sell |
873,269
-119,743
| -12% | -$10.1M | 0.03% | 651 |
|
|
2023
Q3 | $103M | Buy |
993,012
+256,471
| +35% | +$28.6M | 0.04% | 496 |
|
|
2023
Q2 | $89.5M | Buy |
736,541
+182,377
| +33% | +$24.3M | 0.03% | 542 |
|
|
2023
Q1 | $85.1M | Buy |
554,164
+104,588
| +23% | +$17.3M | 0.03% | 515 |
|
|
2022
Q4 | $80.8M | Buy |
449,576
+137,479
| +44% | +$22.5M | 0.03% | 575 |
|
|
2022
Q3 | $36.9M | Sell |
312,097
-115,255
| -27% | -$17.5M | 0.02% | 866 |
|
|
2022
Q2 | $61M | Buy |
427,352
+62,194
| +17% | +$8.89M | 0.03% | 628 |
|
|
2022
Q1 | $62.9M | Sell |
365,158
-346,161
| -49% | -$58.3M | 0.02% | 724 |
|
|
2021
Q4 | $181M | Sell |
711,319
-51,687
| -7% | -$15.1M | 0.05% | 371 |
|
|
2021
Q3 | $294M | Buy |
763,006
+348,592
| +84% | +$129M | 0.09% | 218 |
|
|
2021
Q2 | $97.4M | Sell |
414,414
-51,919
| -11% | -$9.28M | 0.03% | 530 |
|
|
2021
Q1 | $61.1M | Buy |
466,333
+135,544
| +41% | +$19.6M | 0.02% | 728 |
|
|
2020
Q4 | $34.6M | Buy |
330,789
+43,258
| +15% | +$4.38M | 0.01% | 991 |
|
|
2020
Q3 | $20.3M | Buy |
287,531
+14,974
| +5% | +$1.04M | 0.01% | 1162 |
|
|
2020
Q2 | $17.5M | Buy |
272,557
+167,322
| +159% | +$9.16M | 0.01% | 1159 |
|
|
2020
Q1 | $3.15M | Buy |
105,235
+94,626
| +892% | +$2.18M | ﹤0.01% | 2332 |
|
|
2019
Q4 | $208K | Sell |
10,609
-49,245
| -82% | -$874K | ﹤0.01% | 5579 |
|
|
2019
Q3 | $952K | Buy |
59,854
+34,320
| +134% | +$507K | ﹤0.01% | 4005 |
|
|
2019
Q2 | $374K | Buy |
25,534
+16,149
| +172% | +$347K | ﹤0.01% | 4503 |
|
|
2019
Q1 | $191K | Buy |
9,385
+7,185
| +327% | +$133K | ﹤0.01% | 4626 |
|
|
2018
Q4 | $34K | Buy |
+2,200
| New | +$36.2K | ﹤0.01% | 6386 |
|
Other funds holding MRNA
TP
UBS Group's MRNA Position: Q2 2026 in Review
UBS Group increased its Moderna (MRNA) stake by 1.3% in Q2 2026, buying an estimated $2.86M and bringing the position to 4,463,211 shares worth $313M. The position accounts for 0.04% of the portfolio, ranked #454.
UBS Group first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- UBS Group held 4,463,211 shares of Moderna worth $313M as of Q2 2026.
- UBS Group bought 55,304 Moderna shares in Q2 2026, an estimated $2.86M.
- Moderna made up 0.04% of UBS Group's portfolio in Q2 2026, its #454 holding.
- UBS Group first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
- 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.